1
|
Crestini A, Vona R, Lo Giudice M, Sbriccoli M, Piscopo P, Borrelli A, Rivabene R, Ricceri L, Mancini A, Confaloni A. Differentiation-Dependent Effects of a New Recombinant Manganese Superoxide Dismutase on Human SK-N-BE Neuron-Like Cells. Neurochem Res 2018; 44:400-411. [PMID: 30471001 DOI: 10.1007/s11064-018-2686-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Revised: 09/24/2018] [Accepted: 11/16/2018] [Indexed: 11/29/2022]
Abstract
We have recently isolated a new isoform of recombinant manganese superoxide dismutase (rMnSOD) which provides a potent antitumor activity and strongly counteracts the occurrence of oxidative stress and tissue inflammation. This isoform, in addition to the enzymatic action common to all SODs, also shows special functional and structural properties, essentially due to the presence of a first leader peptide that allows the protein to enter easily into cells. Among endogenous antioxidants, SOD constitutes the first line of natural defence against pathological effects induced by an excess of free radicals. Here, we firstly describe the effects of our rMnSOD administration on the proliferant and malignant undifferentiated human neuroblastoma SK-N-BE cell line. Moreover, we also test the effects of rMnSOD in the all trans retinoic-differentiated SK-N-BE neuron-like cells, a quiescent "not malignant" model. While rMnSOD showed an antitumor activity on proliferating cells, a poor sensitivity to rMnSOD overload in retinoid-differentiated neuron-like cells was observed. However, in the latter case, in presence of experimental-induced oxidative stress, overcharge of rMnSOD enhanced the oxidant effects, through an increase of H2O2 due to low activity of both catalase and glutathione peroxidase. In conclusion, our data show that rMnSOD treatment exerts differential effects, which depend upon both cell differentiation and redox balance, addressing attention to the potential use of the recombinant enzyme on differentiated neurons. These facts ultimately pave the way for further preclinical studies aimed at evaluation of rMnSOD effects in models of neurodegenerative diseases.
Collapse
Affiliation(s)
- Alessio Crestini
- Department of Neuroscience, Italian National Institute of Health, Rome, Italy
| | - Rosa Vona
- Biomarkers Unit, Center for Gender-Specific Medicine, Italian National Institute of Health, Rome, Italy
| | - Maria Lo Giudice
- Department of Neuroscience, Italian National Institute of Health, Rome, Italy
| | - Marco Sbriccoli
- Department of Neuroscience, Italian National Institute of Health, Rome, Italy
| | - Paola Piscopo
- Department of Neuroscience, Italian National Institute of Health, Rome, Italy
| | - Antonella Borrelli
- Molecular Biology and Viral Oncology Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, "Fondazione G. Pascale", IRCCS, Naples, Italy
| | - Roberto Rivabene
- Department of Neuroscience, Italian National Institute of Health, Rome, Italy
| | - Laura Ricceri
- Centre for Behavioural Sciences and Mental Health, Italian National Institute of Health, Rome, Italy
| | - Aldo Mancini
- Leadhexa Biotechnologies Inc., San Francisco, CA, USA
| | - Annamaria Confaloni
- Department of Neuroscience, Italian National Institute of Health, Rome, Italy.
| |
Collapse
|
2
|
Moss RW. Cancer and Complementary and Alternative Medicine in Italy: Personal Observations and Historical Considerations. Integr Cancer Ther 2016; 3:173-88. [PMID: 15165505 DOI: 10.1177/1534735404265032] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
This article contains observations and historical considerations on cancer and complementary and alternative medicine (CAM) in Italy, a country that has a great tradition in medical research, going back to the Renaissance. However, Italy does not have a strong tradition of using CAM approaches in the treatment of cancer. While surveys show that the Italian population is eager to learn more about CAM, the medical profession there is largely dismissive of these methods. In 1997-1998, the notorious Luigi Di Bella affair occurred in Italy, when a professor of physiology at Modena proposed a nonconventional approach to cancer treatment, based on the off-label use of somatostatin. This treatment found champions in the media and general public but was opposed by most of the medical profession. Although clinical trials later demonstrated that it had no efficacy, the affair divided Italian public opinion and nearly brought down the national government. Italy no longer has prominent proponents of nonconventional treatments in cancer. However, it continues to have innovative scientists who do important work that is consonant with a CAM approach. This article considers the work of 3 such scientists: Paolo Lissoni, MD, of Monza (Milan), who has carried out numerous clinical trials with the pineal hormone melatonin; Giancarlo Pizza, MD, of Bologna, who has done extensive work on the use of transfer factor and other immunomodulators in the treatment of renal cell and other kinds of cancer; and Aldo Mancini, MD, of Naples, who has isolated a mutated formof Mn-SOD-2 from the growth medium of a unique liposarcoma cell line. These scientists have introduced some flexibility into a rigid state-run hospital system by offering patients innovative treatment options in the context of approved clinical trials.
Collapse
Affiliation(s)
- Ralph W Moss
- Cancer Communications, Inc, PO Box 1076, Lemont, PA 16851, USA
| |
Collapse
|
3
|
Borrelli A, Schiattarella A, Mancini R, Pica A, Pollio ML, Ruggiero MG, Bonelli P, De Luca V, Tuccillo FM, Capasso C, Gori E, Sanseverino M, Carpentieri A, Birolo L, Pucci P, Rommelaere J, Mancini A. A new hexapeptide from the leader peptide of rMnSOD enters cells through the oestrogen receptor to deliver therapeutic molecules. Sci Rep 2016; 6:18691. [PMID: 26725847 PMCID: PMC4698655 DOI: 10.1038/srep18691] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 11/19/2015] [Indexed: 12/31/2022] Open
Abstract
A 24-amino acid leader peptide of a new human recombinant manganese superoxide dismutase can enter cells and carry molecules. Here, we demonstrated that six of the 24 amino acids penetrate cells through a particular gate represented by a specific amino acid sequence of the oestrogen receptor (ER). We analysed the internalization of the synthetic hexapeptide and the cytotoxic activity of the hexapeptide conjugated to cisplatin on a cell line panel. In most cell lines, the hexapeptide delivered an amount of cisplatin that was 2 to 8 times greater than that released by cisplatin when the drug was used alone. This increased delivery increases the therapeutic index of cisplatin and reduces side effects caused by a high dosage or long-term treatment times. We may consider this hexapeptide a new molecular carrier to deliver molecules with therapeutic activity into ER+ cells for diagnostic purposes and clinical or immune therapy.
Collapse
Affiliation(s)
- Antonella Borrelli
- Molecular Biology and Viral Oncology, National Cancer Institute "Fondazione Pascale", Naples, Italy
| | | | - Roberto Mancini
- Department of Biotechnology, Friedrich-Loeffler-Institut, Neustadt, Germany
| | - Alessandra Pica
- Department of Biology, University of Naples, Federico II, Italy
| | | | | | - Patrizia Bonelli
- Molecular Biology and Viral Oncology, National Cancer Institute "Fondazione Pascale", Naples, Italy
| | | | - Franca Maria Tuccillo
- Molecular Biology and Viral Oncology, National Cancer Institute "Fondazione Pascale", Naples, Italy
| | | | - Enrico Gori
- Department of Statistics, University of Udine, Udine, Italy
| | | | - Andrea Carpentieri
- Department of Chemical Sciences, University of Naples, Federico II, Italy
| | - Leila Birolo
- Department of Chemical Sciences, University of Naples, Federico II, Italy
| | - Piero Pucci
- Department of Chemical Sciences, University of Naples, Federico II, Italy
| | - Jean Rommelaere
- Deutsches Krebsforschungszentrum, Infection and Cancer Program, Abt.F010, Heidelberg, Germany
| | - Aldo Mancini
- Laedhexa Biotechnologies Inc., QB3@953, San Francisco, CA, USA
| |
Collapse
|
4
|
The functional role of MnSOD as a biomarker of human diseases and therapeutic potential of a new isoform of a human recombinant MnSOD. BIOMED RESEARCH INTERNATIONAL 2014; 2014:476789. [PMID: 24511533 PMCID: PMC3913005 DOI: 10.1155/2014/476789] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Accepted: 11/19/2013] [Indexed: 01/05/2023]
Abstract
Reactive oxygen species (ROS) are generated as a consequence of metabolic reactions in the mitochondria of eukaryotic cells. This work describes the role of the manganese superoxide dismutase (MnSOD) as a biomarker of different human diseases and proposes a new therapeutic application for the prevention of cancer and its treatment. The paper also describes how a new form of human MnSOD was discovered, its initial application, and its clinical potentials. The MnSOD isolated from a human liposarcoma cell line (LSA) was able to kill cancer cells expressing estrogen receptors, but it did not have cytotoxic effects on normal cells. Together with its oncotoxic activity, the recombinant MnSOD (rMnSOD) exerts a radioprotective effect on normal cells irradiated with X-rays. The rMnSOD is characterized by the presence of a leader peptide, which allows the protein to enter cells: this unique property can be used in the radiodiagnosis of cancer or chemotherapy, conjugating radioactive substances or chemotherapic drugs to the leader peptide of the MnSOD. Compared to traditional chemotherapic agents, the drugs conjugated with the leader peptide of MnSOD can selectively reach and enter cancer cells, thus reducing the side effects of traditional treatments.
Collapse
|
5
|
Mitchell MA, Johnson JE, Pascarelli K, Beeharry N, Chiourea M, Gagos S, Lev D, von Mehren M, Kipling D, Broccoli D. Doxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with alternative lengthening of telomeres. Mol Cancer Ther 2010; 9:682-92. [PMID: 20197395 DOI: 10.1158/1535-7163.mct-09-0705] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Soft tissue sarcomas are a diverse set of fatal human tumors where few agents have demonstrable clinical efficacy, with the standard therapeutic combination of doxorubicin and ifosfamide showing only a 25% to 30% response rate in large multi-institutional trials. Although liposarcomas are the most common histologic form of adult soft tissue sarcomas, research in this area is severely hampered by the lack of experimentally tractable in vitro model systems. To this end, here we describe a novel in vitro model for human pleomorphic liposarcoma. The cell line (LS2) is derived from a pleomorphic liposarcoma that uses the alternative lengthening of telomeres (ALT) mechanism of telomere maintenance, which may be important in modulating the response of this tumor type to DNA-damaging agents. We present detailed baseline molecular and genomic data, including genome-wide copy number and transcriptome profiles, for this model compared with its parental tumor and a panel of liposarcomas covering multiple histologies. The model has retained essentially all of the detectable alterations in copy number that are seen in the parental tumor, and shows molecular karyotypic and expression profiles consistent with pleomorphic liposarcomas. We also show the utility of this model, together with two additional human liposarcoma cell lines, to investigate the relationship between topoisomerase 2A expression and the sensitivity of ALT-positive liposarcomas to doxorubicin. This model, together with its associated baseline data, provides a powerful new tool to develop treatments for this clinically poorly tractable tumor and to investigate the contribution that ALT makes to modulating sensitivity to doxorubicin.
Collapse
Affiliation(s)
- Marcy A Mitchell
- Department of Laboratory Oncology Research, Curtis and Elizabeth Anderson Cancer Institute, Memorial University Medical Center, Savannah, Georgia 31404, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|